argenx SE (ARGX)
| Market Cap | 35.42B |
| Revenue (ttm) | 2.64B |
| Net Income (ttm) | 1.06B |
| Shares Out | 60.98M |
| EPS (ttm) | 15.94 |
| PE Ratio | 33.28 |
| Forward PE | 37.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,609 |
| Open | 586.80 |
| Previous Close | 583.62 |
| Day's Range | 574.86 - 589.90 |
| 52-Week Range | 368.57 - 678.21 |
| Beta | 0.04 |
| Analysts | Strong Buy |
| Price Target | 709.29 (+23.26%) |
| Earnings Date | Jul 24, 2025 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price forecast is $709.29, which is an increase of 23.26% from the latest price.
News
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
argenx Announces Results of Annual General Meeting of Shareholders
May 28, 2025 – 10:01 PM C ET
Argenx Q1 Earnings: Less Than Perfect Report Gets Punished
Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the M...
argenx SE (ARGX) Q1 2025 Earnings Call Transcript
argenx SE (NASDAQ:ARGX) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeir...
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opin...
argenx to Present at BofA Securities 2025 Health Care Conference
May 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ...
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase...
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune d...
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option o...
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term...
Stock Picks From Seeking Alpha's March 2025 New Analysts
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hau...
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and th...
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA...
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Highlights 2025 Strategic Priorities
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
VYVDURA ® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP
argenx to Present at Upcoming Investor Conferences
November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...